NJ-based Novartis to lay off 427 as drug patent expires
Global drugmaker Novartis will lay off 427 employees who report to the company's East Hanover headquarters this spring and ...
Daily Voice7h
Pharma Giant Cutting 400+ More NJ Jobs Ahead Of Major Drug Patent's Expiration
Pharmaceutical company Novartis is laying off more than 400 US employees who report to its East Hanover facility as part of a ...
FDA Approves Novartis Drug for Rare Kidney Disease Treatment
Novartis wins FDA approval for the label expansion of Fabhalta for a third indication - treatment of adults with C3 ...
Fierce Pharma10h
Novartis links music and science in corporate campaign tied to Eurovision sponsorship
Novartis was announced as an official partner of this year’s Eurovision competition last fall, after the song entry from ...
FDA Approves Expanded Use Of Novartis Rare Disease Drug As Only Treatment For Rare Type Of Kidney Disease
Novartis' Fabhalta receives FDA approval for C3 glomerulopathy, expanding its kidney disease portfolio as global regulatory ...
Managed Healthcare Executive11h
FDA Approves Novartis’ Oral Fabhalta as First Treatment for C3G.
The FDA on Thursday approved Fabhalta (iptacopan) to treat complement 3 glomerulopathy (CG3), a progressive, ultrarare kidney ...
BioSpace11h
Novartis’ Fabhalta Approved as First Therapy for Rare Kidney Disease
This is the third indication for Fabhalta after Novartis won FDA approval of the small molecule in paroxysmal nocturnal hemoglobinuria and primary immunoglobulin A nephropathy.
Fierce Pharma11h
Novartis snags FDA nod for Fabhalta in another kidney disease but leaves room for rival Apellis
Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...
The American Journal of Managed Care11h
FDA Approves Oral Iptacopan for C3 Glomerulopathy
The FDA approved oral iptacopan (Fabhalta; Novartis) to reduce proteinuria in adults with C3 glomerulopathy (C3G), according ...
pharmaphorum13h
Fabhalta is first FDA-approved therapy for rare disease C3G
Novartis has a third FDA-approved indication for its oral therapy for complement-mediated diseases – Fabhalta – after getting ...
Merck Vs. Bristol-Myers Squibb: Which Pharma Stock Should You Buy
Merck and Bristol-Myers Squibb are key players in cancer treatment. Find out why MRK and BMY stocks have different prospects ...